Latest SPAC Liquidations: LF Capital Acquisition Corp. II
LF Capital Acquisition Corp. II (LFAC) to Liquidate on October 3, 2023
LF Capital Acquisition Corp. II (Nasdaq: LFAC), today announced that the directors of the Company have determined to dissolve and liquidate the Company.
The redemption of the Public Shares is expected to be completed on or about October 3, 2023 (the “Redemption Date”). At the close of business on the business day prior to the Redemption Date, the Company will stop trading its Public Shares, and each Public Share held at that time will represent the right to receive the redemption amount of approximately $10.87 (without giving effect to any interest that may be withdrawn to pay for taxes and dissolution expenses).
READ
Flag Ship Acquisition Corporation (NASDAQ:FSHP) has entered into a definitive agreement to combine with Great Future under so far undisclosed terms. Transaction Overview Flag Ship has about $71.6 million in its current trust and has until September 20, 2025 to complete a business combination but may extend up to nine times for one month each...
At the SPAC of Dawn SPAC momentum has not waned amid the market rally as three more SPACs are angling to price their IPOs by this evening, adding to two others and went public earlier this week. This would bring April’s tally to nine SPAC IPOs after just three in March. It has not been...
New Providence Acquisition Corp. III (NASDAQ:NPACU) announced the pricing of its $261 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NPACU”, Thursday, April 24, 2025. The new SPAC aims to combine with a consumer target that has the potential to generate attractive risk-adjusted returns. New Providence III’s...
Cantor Equity Partners Inc. (NASDAQ:CEP) has entered into a definitive agreement to combine with Twenty One Capital at an enterprise value of $3.6 billion, or 1x its future net asset value (NAV). Twenty One Capital aims to secure a sizeable Bitcoin holding and leverage it for financial services products as well as Bitcoin-focused media offerings....
Voyager (NASDAQ:VACH) has signed a definitive agreement to combine with biotech firm VERAXA at an enterprise value of $1.38 billion. Heidelberg, Germany-based VERAXA is developing cancer treatments with its most advanced candidate targeting acute myeloid leukemia (AML). The combined company is expected to trade on the Nasdaq under the symbol “VERX” once the deal is...